Howard Robin | President, Chief Executive Officer |
Gil Labrucherie | Chief Financial Officer |
Dr. Steve Doberstein | Chief R&D Officer |
Dr. Jonathan Zalevsky | Chief Scientific Officer |
Mary Tagliaferri | Chief Medical Officer |
Jennifer Ruddock | Senior Vice President, Investor Relations |
Chris Shibutani | Cowen |
Jessica Fye | JPMorgan |
Bert Hazlett | BTIG |
Difei Yang | Mizuho Securities |
Andy Hsieh | William Blair |
David Steinberg | Jefferies |
Good day ladies and gentlemen, and welcome to the Nektar Therapeutics Q4 and Year End 2017 Financial Results Call. At this time all participants are in a listen-only mode. Later we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions] As a reminder, this conference call may be recorded. I would now like to introduce your host for today's conference, Ms.